Publications

2017 | 2016 | 2015 | 2014 | 2008 | 2006 | 2004

2017

Goyal L*, Saha SK*, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. (2017). Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaCancer Discovery, 7:252-263. *These authors contributed equally.

2016

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo J, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RJ, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. (2016). Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinomaCancer Discovery, 6:727-39.

Saha SK, Zhu AX, Fuchs CS, Brooks GA. (2016). Forty-Year Trends in Cholangiocarcinoma Incidence in the United States: Intrahepatic Disease on the RiseOncologist, 21:594-9.

2015

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Desphande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. (2015). Prognosis and Clinicopathologic Features of Patients with Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaOncologist, 20:1019-27.

2014

Saha SK*, Parachoniak CA*, Ghanta KS, Fitamant JF, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Desphande V, Zhu AX, Hezel AF, Yen K, Straley K, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N. (2014). Mutant IDH inhibits HNF4a to block hepatocyte differentiation and promote biliary cancerNature, 513:110-4. *These authors contributed equally.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. (2014). Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaClin Cancer Res, 20:1884-90.

Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG Jr, Bardeesy N, Wong KK. (2014). D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in miceGenes Dev, 28:479-90.

2008

Oganesyan G*, Saha SK*, Pietras EM, Guo B, Miyahira AK, Zarnegar B, Cheng G. (2008). IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody productionJ Biol Chem 283:802-8; *These authors contributed equally.

2006

Saha SK*, Pietras EM*, He JQ, Kang JR, Liu S, Oganesyan G, Shahangian A, Zarnegar B, Shiba TL, Wang Y and Cheng G. (2006). Regulation of antiviral responses by a direct and specific interaction between TRAF3 and CardifEMBO Journal, 25:3257-63. *These authors contributed equally.

Oganesyan G*, Saha SK*, He JQ, Guo B, Perry AK, Zarnegar B, Shahangian A, and Cheng G. (2006). Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral responseNature, 439:208-11. *These authors contributed equally.

2004

O’Connell RM*, Saha SK*, Vaidya SA*, Bruhn KW, Miranda GA, Zarnegar B, Perry AK, Nguyen BD, Lane TF, Taniguchi T, MillerJF and Cheng G. (2004). Type I interferon production enhances susceptibility to Listeria monocytogenes infectionJournal of Experimental Medicine, 200:437-45. *These authors contributed equally.